文献速递认知障碍与痴呆

用残差法测量衰老与阿尔茨海默病中的抵抗力和韧性:系统综述与荟萃分析

Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods: A Systematic Review and Meta-analysis.
PubMed 文献 · Neurology · 2021-07-15

该系统综述检索PubMed和Web of Science至2020年3月,纳入54项使用残差法量化脑与认知衰老中抵抗力或韧性的研究,其中10项进入荟萃分析。荟萃分析显示,抵抗力水平与痴呆/AD进展风险相关(HR 1.12,95%CI 1.07-1.17,p<0.0001),韧性水平与进展风险相关(HR 0.46,95%CI 0.32-0.68,p<0.001),韧性还与认知下降速率相关(β 0.05,95%CI 0.01-0.08,p<0.01)。作者认为残差法可捕捉临床有意义信息,但方法学标准化仍需加强。

要点

  • 残差法可量化个体在给定风险或脑损伤下避免或应对衰老与AD的“优于或差于预期”能力。
  • 荟萃分析中抵抗力水平与痴呆/AD进展风险相关(HR 1.12)。
  • 韧性水平与痴呆/AD进展风险相关(HR 0.46),并与认知下降速率相关。

核心结论

  • 本综述与荟萃分析支持残差法是测量衰老和AD中韧性与抵抗力的合适方法,可捕捉临床有意义的信息。
  • 仍需更严格的方法学标准化,以提高研究间可比性并最终用于临床实践。

研究设计与样本

  • 系统检索PubMed和Web of Science数据库至2020年3月,最终纳入54项符合标准的研究。
  • 其中10项研究适合进行荟萃分析,评估残差法测量的韧性与抵抗力同纵向认知和临床结局的关联。

主要发现

  • 纳入研究分别使用残差法量化抵抗力(n=33)、认知韧性(n=23)和脑韧性(n=2)。
  • 荟萃分析显示抵抗力水平与痴呆/AD进展风险相关:HR 1.12(95%CI 1.07-1.17),p<0.0001。
  • 荟萃分析显示韧性水平与痴呆/AD进展风险相关:HR 0.46(95%CI 0.32-0.68),p<0.001。
  • 韧性还与认知下降速率相关:β 0.05(95%CI 0.01-0.08),p<0.01。

关键数值与推荐

  • 残差法定义为利用回归分析的残差量化在给定风险或脑损伤水平下避免(抵抗力)或应对(韧性)“优于或差于预期”的能力。
  • 文献显示残差测量指标的推导与验证存在相当大的方法学变异。
  • 荟萃分析中抵抗力与痴呆/AD进展风险的HR为1.12(95%CI 1.07-1.17),p<0.0001。
  • 荟萃分析中韧性与痴呆/AD进展风险的HR为0.46(95%CI 0.32-0.68),p<0.001。
  • 韧性与认知下降速率的β为0.05(95%CI 0.01-0.08),p<0.01。

临床怎么用

  • 残差法测量的韧性与抵抗力可提供衰老和AD中超越传统风险因素的临床相关信息。
  • 在临床或研究应用中需注意不同研究间残差指标推导与验证方法不一致,解读时应结合具体方法。
  • 推广至临床实践前仍需方法学标准化以提高可比性。

局限性

  • 文献中残差测量指标的推导和验证存在显著方法学差异,影响研究间可比性。
  • 仅10项研究适合荟萃分析,且不同研究间方法学差异较大。
  • 作者指出需要更严格的方法学标准化,提示当前证据尚不足以直接用于临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: There is a lack of consensus on how to optimally define and measure resistance and resilience in brain and cognitive aging. Residual methods use residuals from regression analysis to quantify the capacity to avoid (resistance) or cope (resilience) "better or worse than expected" given a certain level of risk or cerebral damage. We reviewed the rapidly growing literature on residual methods in the context of aging and Alzheimer disease (AD) and performed meta-analyses to investigate associations of residual method-based resilience and resistance measures with longitudinal cognitive and clinical outcomes. METHODS: A systematic literature search of PubMed and Web of Science databases (consulted until March 2020) and subsequent screening led to 54 studies fulfilling eligibility criteria, including 10 studies suitable for the meta-analyses. RESULTS: We identified articles using residual methods aimed at quantifying resistance (n = 33), cognitive resilience (n = 23), and brain resilience (n = 2). Critical examination of the literature revealed that there is considerable methodologic variability in how the residual measures were derived and validated. Despite methodologic differences across studies, meta-analytic assessments showed significant associations of levels of resistance (hazard ratio [HR] [95% confidence interval (CI)] 1.12 [1.07-1.17]; p < 0.0001) and levels of resilience (HR [95% CI] 0.46 [0.32-0.68]; p < 0.001) with risk of progression to dementia/AD. Resilience was also associated with rate of cognitive decline (β [95% CI] 0.05 [0.01-0.08]; p < 0.01). DISCUSSION: This review and meta-analysis supports the usefulness of residual methods as appropriate measures of resilience and resistance, as they capture clinically meaningful information in aging and AD. More rigorous methodologic standardization is needed to increase comparability across studies and, ultimately, application in clinical practice.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Bocancea DI, van Loenhoud AC, Groot C, et al. Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods: A Systematic Review and Meta-analysis. Neurology. 2021. PMID: 34266918. doi:10.1212/WNL.0000000000012499

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。